<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02085980</url>
  </required_header>
  <id_info>
    <org_study_id>ELEN13-VVA-MK01</org_study_id>
    <nct_id>NCT02085980</nct_id>
  </id_info>
  <brief_title>Clinical Investigation to Assess the Safety and Efficacy of the Laser for the Treatment of Vulvovaginal Atrophy</brief_title>
  <official_title>Clinical Investigation to Assess the Safety and Efficacy of the Laser for the Treatment of Vulvovaginal Atrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>El. En. SpA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Christ Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>El. En. SpA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and the efficacy of a laser in the&#xD;
      treatment of vulvovaginal atrophy (VVA), that is to assess the change in the severity of the&#xD;
      vaginal dryness symptom, by means of a visual analogic scale (10 cm VAS).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The laser handpiece (probe) will be deposited in the vaginal canal and the laser energy will&#xD;
      be delivered through the handpiece. Subjects will receive a total of three (3) treatments&#xD;
      every six (6) weeks (+/-1 week). Subjects will return one week (+/- 3 days) post the first&#xD;
      treatment, as well as three (3) months (+/- 2 weeks) and twelve (12) months (+/- 2 weeks)&#xD;
      post the third treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Main Outcome of the Study is the Efficacy of the Laser Procedure, Intended as the Amelioration of 50% of the Severity of the Vaginal Dryness at 12 Months, Compared With Baseline</measure>
    <time_frame>Baseline and at follow up visit at 12 months post last treatment</time_frame>
    <description>The main outcome of the study is the efficacy of the laser procedure, intended as the amelioration of 50% of the severity of the vaginal dryness at 12 months, compared with baseline.&#xD;
The change in the vaginal dryness symptom has been assessed by means of a visual analogic scale (10 cm VAS).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Vulvovaginal Atrophy</condition>
  <arm_group>
    <arm_group_label>Laser Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Laser Treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Laser treatment</intervention_name>
    <description>The laser handpiece (probe) will be deposited in the vaginal canal and the laser energy will be delivered through the handpiece</description>
    <arm_group_label>Laser Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy non-smoking post menopausal women with absence of menstruation of at least 12&#xD;
             months&#xD;
&#xD;
          -  Exhibiting VVA symptoms&#xD;
&#xD;
          -  Prolapse staged &lt; II, according to the pelvic organ prolapse quantification&#xD;
             (ICS-POP-Q) system&#xD;
&#xD;
          -  Have not had procedures in the anatomical area through 6 months prior to treatment&#xD;
&#xD;
          -  Understand and accept the obligation and is logistically able to present for all&#xD;
             scheduled follow-up visits&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  • Acute or recurrent urinary tract infection (UTI), or genital infection (e.g. herpes&#xD;
             candida).&#xD;
&#xD;
               -  Prolapse staged ≥ II, according to the pelvic organ prolapse quantification&#xD;
                  (ICS-POP-Q) system&#xD;
&#xD;
               -  Any serious disease, or chronic condition, that could interfere with the study&#xD;
                  compliance&#xD;
&#xD;
               -  Previously undergone reconstructive pelvic surgery&#xD;
&#xD;
               -  Have used vaginal creams, moisturizers, lubricants or homeopathic preparations&#xD;
                  for at least 3 months&#xD;
&#xD;
               -  A history of thrombophlebitis&#xD;
&#xD;
               -  A history of acute infections&#xD;
&#xD;
               -  A history of heart failure&#xD;
&#xD;
               -  Received or is anticipated to receive antiplatelets, anticoagulants,&#xD;
                  thrombolytics, vitamin E or anti inflammatories within 2 weeks pre treatment&#xD;
&#xD;
               -  Any medical condition, that, in the investigator's opinion would interfere with&#xD;
                  the patient's participation in the study&#xD;
&#xD;
               -  Taking medications that are photosensitive&#xD;
&#xD;
               -  A history of keloid formation&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mickey Karram, MK</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Physician, The Christ Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric Sokol, MD</last_name>
    <role>Study Director</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94306</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Carl and Edyth Lindner Center for Research and Education at The Christ Hospital</name>
      <address>
        <city>West Chester</city>
        <state>Ohio</state>
        <zip>45069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>van der Laak JA, de Bie LM, de Leeuw H, de Wilde PC, Hanselaar AG. The effect of Replens on vaginal cytology in the treatment of postmenopausal atrophy: cytomorphology versus computerised cytometry. J Clin Pathol. 2002 Jun;55(6):446-51.</citation>
    <PMID>12037029</PMID>
  </results_reference>
  <verification_date>February 2017</verification_date>
  <study_first_submitted>March 10, 2014</study_first_submitted>
  <study_first_submitted_qc>March 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2014</study_first_posted>
  <results_first_submitted>May 11, 2021</results_first_submitted>
  <results_first_submitted_qc>May 11, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 4, 2021</results_first_posted>
  <last_update_submitted>May 11, 2021</last_update_submitted>
  <last_update_submitted_qc>May 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Laser Treatment</title>
          <description>Laser Treatment&#xD;
Laser treatment: The laser handpiece (probe) will be deposited in the vaginal canal and the laser energy will be delivered through the handpiece</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Laser Treatment</title>
          <description>Laser Treatment&#xD;
Laser treatment: The laser handpiece (probe) will be deposited in the vaginal canal and the laser energy will be delivered through the handpiece</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.6" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Main Outcome of the Study is the Efficacy of the Laser Procedure, Intended as the Amelioration of 50% of the Severity of the Vaginal Dryness at 12 Months, Compared With Baseline</title>
        <description>The main outcome of the study is the efficacy of the laser procedure, intended as the amelioration of 50% of the severity of the vaginal dryness at 12 months, compared with baseline.&#xD;
The change in the vaginal dryness symptom has been assessed by means of a visual analogic scale (10 cm VAS).</description>
        <time_frame>Baseline and at follow up visit at 12 months post last treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Laser Treatment</title>
            <description>Laser Treatment&#xD;
Laser treatment: The laser handpiece (probe) will be deposited in the vaginal canal and the laser energy will be delivered through the handpiece</description>
          </group>
        </group_list>
        <measure>
          <title>The Main Outcome of the Study is the Efficacy of the Laser Procedure, Intended as the Amelioration of 50% of the Severity of the Vaginal Dryness at 12 Months, Compared With Baseline</title>
          <description>The main outcome of the study is the efficacy of the laser procedure, intended as the amelioration of 50% of the severity of the vaginal dryness at 12 months, compared with baseline.&#xD;
The change in the vaginal dryness symptom has been assessed by means of a visual analogic scale (10 cm VAS).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Laser Treatment</title>
          <description>Laser Treatment&#xD;
Laser treatment: The laser handpiece (probe) will be deposited in the vaginal canal and the laser energy will be delivered through the handpiece</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Mickey Karram</name_or_title>
      <organization>The Christ Hospital - Cincinnati, OH</organization>
      <phone>(513) 463-2500</phone>
      <email>mickey.karram@thechristhospital.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

